ELSE NUTRITION HOLDINGS INC. (TSX: BABY) (OTCQX: BABYF) (FSE: 0YL)
(the “Company”) is pleased to announce that it has closed a second
tranche of a private placement pursuant to the convertible security
funding agreement with Lind Global Fund II, LP, an entity managed
by The Lind Partners, LLC, a New York-based institutional fund
manager, for net proceeds of US$1,000,000 after deduction of the
original issue discount and closing fees.
Pursuant to the closing, the Company issued a
convertible security (the “Second Convertible Security”) with a two
year term and a face value of US$1,200,000, and 4,159,866 common
share purchase warrants exercisable into common shares in the
capital of the Company (“Shares”) for a period of 48 months from
the date of issuance at an exercise price of C$0.32019 per
Share.
The Second Convertible Security has a 36-month
maturity date and will be convertible into Shares after completion
of a 120 day lock-up period. Lind will be able to convert 1/20th of
the face value each month at a conversion price equal to 85% of the
five-day volume weighted average price of the Shares immediately
prior to each conversion, subject to a right to increase
conversions in certain circumstances. The outstanding face value of
the Second Convertible Security, after 180 days, may be repaid in
cash at the discretion of the Company, with a 5% premium (the
“Buy-Back Right”). Should the Company exercise its
Buy-Back Right, Lind would have the option to convert up to 33.3%
of the face value of the Second Convertible Security into
Shares.
The proceeds from the issuance of the Second
Convertible Security will be applied to clinical trials in
connection with FDA and other application processes, as well as
general working capital.
The Company has obtained approval of Toronto
Stock Exchange (“TSX”) and shareholder approval
for the transactions described above. Shares issued pursuant to any
conversions would be issued under TSX private placement rules and
would not be freely tradable for four months and one day following
closing and would be subject to restrictions under applicable
Canadian and United States securities laws.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy nor shall there be any
sale of the securities offered in any jurisdiction in which such
offer, solicitation, or sale would be unlawful. The securities
offered have not been registered under the United States Securities
Act of 1933, as amended (the “U.S. Securities
Act”), or applicable state securities laws, and may not be
offered or sold to, or for the account or benefit of, persons in
the United States or U.S. persons (as both such terms are defined
in Regulation S promulgated under the U.S. Securities Act) absent
registration or an applicable exemption from such registration
requirements.
About Else Nutrition Holdings
Inc.
Else Nutrition Holdings Inc. is a food and
nutrition company in the international expansion stage focused on
developing innovative, clean, and plant-based food and nutrition
products for infants, toddlers, children, and adults. Its
revolutionary, plant-based, non-soy formula is a clean-ingredient
alternative to dairy-based formulas. Since launching its
Plant-Based Complete Nutrition for Toddlers, made of whole foods,
almonds, buckwheat, and tapioca, the brand has received thousands
of powerful testimonials and reviews from parents, gained national
retailer support, and achieved rapid sales growth.
Awards and Recognition:
- “2017 Best Health and Diet
Solutions” award at Milan's Global Food Innovation Summit
- #1 Best Seller on Amazon in the
Fall of 2020 in the New Baby & Toddler Formula Category
- “Best Dairy Alternative” Award 2021
at World Plant-Based Expo
- Nexty Award Finalist at Expo West
2022 in the Plant-Based lifestyle category
- During September 2022, Else Super
Cereal reached the #1 Best Seller in Baby Cereal across all brands
on Amazon
For more information, visit
www.elsenutrition.com or @elsenutrition on Facebook and
Instagram.
About The Lind Partners
The Lind Partners manages institutional funds
that are leaders in providing growth capital to small- and mid-cap
companies publicly traded in the US, Canada, Australia and the UK.
Lind’s funds make direct investments ranging from US$1 to US$30
million, invest in syndicated equity offerings and selectively buy
on market. Having completed more than 150 direct investments
totaling over US$1.5 Billion in transaction value, Lind’s funds
have been flexible and supportive capital partners to investee
companies since 2011. For more information, please visit
http://www.thelindpartners.com.
For more information,
contact:Mrs. Hamutal Yitzhak, CEO, Co-Founder &
DirectorELSE Nutrition Holdings Inc.E: hamutaly@elsenutrition.com
P: +972(0)3-6445095
Mr. Sokhie Puar, Lead Director of Else
NutritionE: sokhiep@elsenutrition.com P : 604-603-7787
Investor Relations Contact:
Alexandra SchiltCrescendo
Communications, LLCOffice: (212) 671-1020Email:
baby@crescendo-ir.com
Caution Regarding Forward-Looking
Statements
This press release contains statements that may
constitute “forward-looking statements” within the meaning of
applicable securities legislation. Forward-looking statements are
typically identified by words such as “will” or similar
expressions. Forward-looking statements in this press release
include but are not limited to, statements with respect to the use
of funds in respect of the Second Convertible Security. These
forward-looking statements are made as of the date of this press
release. Such forward-looking statements reflect current estimates,
beliefs and assumptions, which are based on management’s perception
of current conditions and expected future developments, as well as
other factors management believes are appropriate in the
circumstances. Although the Company believes the forward-looking
statements in this press release are reasonable, it can give no
assurance that the expectations and assumptions in such statements
will prove to be correct. The Company cautions investors that any
forward-looking statements by the Company are not guarantees of
future results or performance, and are subject to risks,
uncertainties, assumptions and other factors which could cause
events or outcomes to differ materially from those expressed or
implied by such forward-looking statements. Such factors and
assumptions include, among others, variations in market conditions;
currency exchange rates; the Company’s ability to obtain any
necessary permits, consents or authorizations required for its
activities; the Company’s ability to access further funding, to
continue its projected growth, or to be fully able to implement its
business strategies. In addition, there are known and unknown risk
factors which could cause our actual results, performance or
achievements to differ materially from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Actual results may differ from the
estimates, beliefs and assumptions expressed or implied in the
forward-looking statements. Readers are cautioned not to place
undue reliance on any forward-looking statements, which reflect
management’s expectations only as of the date of this press
release. The Company disclaims any obligation to update or revise
any forward-looking statements, whether as a result of new
information, future events or otherwise, except as required by
law.
Else Nutrition (TSX:BABY)
Gráfico Histórico do Ativo
De Dez 2024 até Jan 2025
Else Nutrition (TSX:BABY)
Gráfico Histórico do Ativo
De Jan 2024 até Jan 2025